Commodore Capital LP Lowers Holdings in Definium Therapeutics, Inc. $DFTX

Commodore Capital LP lowered its stake in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) by 35.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,225,000 shares of the company’s stock after selling 1,775,000 shares during the period. Definium Therapeutics accounts for about 1.9% of Commodore Capital LP’s investment portfolio, making the stock its 20th largest position. Commodore Capital LP owned about 3.27% of Definium Therapeutics worth $38,023,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Stoneridge Investment Partners LLC increased its holdings in Definium Therapeutics by 7.5% in the 3rd quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock valued at $136,000 after acquiring an additional 804 shares during the last quarter. Cerity Partners LLC increased its holdings in shares of Definium Therapeutics by 2.4% in the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after purchasing an additional 1,165 shares during the last quarter. Creative Planning lifted its position in shares of Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after buying an additional 1,655 shares in the last quarter. Rathbones Group PLC lifted its position in shares of Definium Therapeutics by 7.1% in the third quarter. Rathbones Group PLC now owns 30,200 shares of the company’s stock worth $356,000 after buying an additional 2,000 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

Insider Buying and Selling at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 11,276 shares of the firm’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the transaction, the insider directly owned 282,576 shares in the company, valued at $3,715,874.40. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the sale, the chief executive officer owned 778,477 shares of the company’s stock, valued at $10,236,972.55. This represents a 3.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 42,667 shares of company stock valued at $561,071 in the last three months. Company insiders own 2.26% of the company’s stock.

Analyst Upgrades and Downgrades

DFTX has been the subject of a number of research reports. Royal Bank Of Canada increased their target price on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Needham & Company LLC reiterated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Chardan Capital upgraded shares of Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Robert W. Baird set a $37.00 target price on shares of Definium Therapeutics in a research report on Thursday, January 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $35.70.

Definium Therapeutics Stock Performance

DFTX stock opened at $18.06 on Friday. Definium Therapeutics, Inc. has a twelve month low of $4.70 and a twelve month high of $19.62. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -8.48 and a beta of 2.56. The business’s fifty day simple moving average is $16.58 and its two-hundred day simple moving average is $13.40. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.